Chief Financial Officer and Executive Vice President
Ms. Dier joined Ultragenyx in October 2020. She is responsible for leading the corporate finance, strategy, investor relations, corporate communications, and information technology functions and is a member of the executive team.
Ms. Dier joins Ultragenyx from Portola Pharmaceuticals, where she served as Chief Financial Officer from 2006 to 2018 when her role was expanded to include Chief Business Officer from 2018 through its acquisition by Alexion Pharmaceuticals in 2020. During her tenure at Portola, she successfully led a series of private, public, and alternative financings and led the company through its pivotal transition into a commercial organization. Prior to Portola, she served as Vice President of Investor Relations at Chiron Corporation from 2003 to 2006. Earlier in her career she worked as an investment banker at Prudential Securities, and prior to that was in the audit department of KPMG Peat Marwick.
Ms. Dier holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles. Ms. Dier serves on the Board of Directors of ORIC Pharmaceuticals, Prelude Therapeutics, and Synthakine, Inc.